News & Events zu Artiva Biotherapeutics Inc (ARTV)ARTVArtiva Biotherapeutics Inc

Artiva Biotherapeutics Files $400M Mixed Securities Shelf

Artiva Biotherapeutics files $400M mixed securities shelf

Artiva Biotherapeutics Raises $300 Million in Funding

"The second quarter was transformative for Artiva. The clinical and translational data presented at EULAR reinforced AlloNK's potential to drive deep B-cell depletion and meaningful clinical responses, with a tolerability profile supportive of outpatient administration. RMAT designation for refractory rheumatoid arthritis, together with FDA alignment on our Phase 3 design, further supports our advancement of AlloNK into registrational development," said Fred Aslan, chief executive officer of Artiva Biotherapeutics. "Having raised approximately $300 million in an underwritten offering, we are well capitalized to initiate and execute our planned Phase 3 trial in refractory RA and continue advancing AlloNK across B-cell-driven autoimmune diseases."

Artiva Biotherapeutics Reports Positive Initial Clinical Data for AlloNK

Artiva Biotherapeutics announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab. As of the April 3 data cutoff, the initial clinical dataset includes 21 refractory RA patients with at least 12 weeks of follow-up, including 13 patients with six months of follow-up, from Artiva's company-sponsored Phase 2a basket trial and an investigator-initiated basket trial evaluating AlloNK in B-cell driven autoimmune diseases. The broader autoimmune dataset also includes 11 SjD patients and five SSc patients, including seven SjD patients and four SSc patients with at least six months of follow-up. Artiva also announced alignment with the FDA on a single registrational randomized controlled trial design for AlloNK in refractory RA expected to enroll approximately 150 RA patients who have had an inadequate response to two or more biologic or targeted synthetic disease modifying anti-rheumatic drugs of distinct classes. Patients are expected to be randomized 2:1 to receive AlloNK plus rituximab or rituximab alone, with ACR50 response at six months as the primary efficacy endpoint. As of April 30 more than 70 autoimmune patients had initiated treatment with AlloNK across ongoing clinical trials, with more than 40 clinical sites activated globally. All patients have been treated in the outpatient setting, with the majority treated in community rheumatology clinics, providing a strong foundation to support Artiva's planned Phase 3 registrational trial in refractory RA.